These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X, Carreira PE, Diaz Gonzalez F, Black CM, van den Hoogen FH. Ann Rheum Dis; 2009 Sep; 68(9):1433-9. PubMed ID: 18782794 [Abstract] [Full Text] [Related]
24. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP. Depress Anxiety; 2007 Sep; 24(1):41-52. PubMed ID: 16845641 [Abstract] [Full Text] [Related]
25. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R. Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455 [Abstract] [Full Text] [Related]
26. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Roth T, White D, Schmidt-Nowara W, Wesnes KA, Niebler G, Arora S, Black J. Clin Ther; 2006 May; 28(5):689-706. PubMed ID: 16861091 [Abstract] [Full Text] [Related]
27. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R. Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280 [Abstract] [Full Text] [Related]
33. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R, Schreiber C. Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501 [Abstract] [Full Text] [Related]
38. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B, RNF Study Group. Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727 [Abstract] [Full Text] [Related]